Ironwood Pharmaceuticals (Ironwood ) and Astellas Pharma have entered into an agreement providing Astellas exclusive rights to develop and commercialise the investigational compound linaclotide in Japan, Indonesia, Korea,
Teva Pharmaceutical (Teva) is seeking to amend its existing complaint against Momenta Pharmaceuticals/Sandoz to include patent infringement of three additional patents related to the characterisation of Copaxone (glatiramer
The US Department of Veterans Affairs (VA) has awarded a $1.84m grant to Diamyd, a wholly-owned subsidiary of Diamyd Medical, to support the development of Nerve Targeting Drug
GlaxoSmithKline (GSK) and Genmab’s antibody Arzerra, which has been approved for use in patients with chronic lymphocytic leukemia (CLL) by the US Food and Drug Administration (FDA), will
Pfizer China and BMP Sunstone have entered into a strategic partnership to import, distribute and promote Depo-Provera (Medroxy-progesterone Acetate), a Pfizer product used to treat endometriosis, in China.
Spectrum Pharmaceuticals (Spectrum) and Nippon Kayaku have entered into an exclusive collaboration for the development and commercialisation of Apaziquone in Asia. Apaziquone is an antineoplastic agent currently being
Immunovaccine has signed a collaborative agreement with the National Cancer Institute (NCI) in Maryland, US. The research collaboration involves formulating NCI’s cancer vaccine antigens in DepoVax, Immunovaccine’s vaccine
Dara BioSciences’s compound for Type 2 diabetes (T2D) has demonstrated superior performance to comparator drugs at the Cambridge Healthtech Institute’s Conference, ‘Targeting Diabetes with Novel Therapeutics.’ Mary Kay
Life Technologies, has signed a definitive agreement to acquire BioTrove, for an undisclosed amount. This acquisition builds on a collaboration that Applied Biosystems entered into with BioTrove in
Bristol-Myers Squibb and Alder Biopharmaceuticals have entered into a global agreement for the development and commercialisation of ALD518. ALD518 is a novel biologic that has completed Phase IIa
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.